Publication details

Pacientka s chronickou myeloidní leukemií s rezistencí a/nebo nesnášenlivostí léčby třemi tyrosinkinázovými inhibitory

Title in English The patient with chronic myeloid leukemia, resistant and/or intolerant to three tyrosine kinase inhibitors
Authors

ŽÁČKOVÁ Daniela

Year of publication 2016
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords chronic myeloid leukemia; tyrosine kinase inhibitors; imatinib; dasatinib; nilotinib; ponatinib; T315I mutation; resistence; intolerance
Description Treatment with tyrosine kinase inhibitors (TKI) dramatically improved prognosis of the patients with chronic myeloid leukemia (CML). Currently, three TKI are recommended and approved for the first line therapy: imatinib, dasatinib, and nilotinib. In case of resistance and/or intolerance to first line agents, two more drugs are approved, bosutinib and ponatinib. Ponatinib is the only agent able to inhibit multi-resistant mutation T315I. Neither ponatinib nor bosutinib are standardly reimbursed by the insurance companies in the Czechia, however they can be requested and finally reimbursed by a special tool, § 16 of the Low on Public Insurance. Presented case report describes successful therapy with ponatinib in CML patient resistant and/or intolerant to previous treatment with all currently available TKI in our country, imatinib, nilotinib and dasatinib.

You are running an old browser version. We recommend updating your browser to its latest version.

More info